Investor Presentaiton
Transaction summary
.
Enterprise value of approximately $1.0B(1) (€950M)
Transaction details
●
All-cash consideration, to be financed with existing cash and debt capacity
Financial highlights
Timing
•
CY 2021 PF Revenue of $83M(1,2) and PF Adj. EBITDA of $35M(1,2)
Strong double-digit organic growth profile
-
CY 2019-21 organic revenue CAGR: 14% (3)
Immediately accretive to non-GAAP EPS (4)
Closing expected in 2H of CY 2022
Subject to regulatory clearances
1. Based on a EUR/USD rate of 1.053.
2. PF Revenue includes adjustments for acquisitions, and PF Adj. EBITDA includes adjustments for acquisitions, income from JVs, and other customary add-backs for non-recurring items.
3. Based on pro forma revenue adjusted for acquisitions.
4. Post deal close
92022 ResMed. Company confidential.View entire presentation